Investment Analysts’ Weekly Ratings Updates for Adaptive Biotechnologies (ADPT)

A number of firms have modified their ratings and price targets on shares of Adaptive Biotechnologies (NASDAQ: ADPT) recently:

• 2/8/2026 – Adaptive Biotechnologies was upgraded by Wall Street Zen from “hold” to “buy”.
• 2/6/2026 – Adaptive Biotechnologies had its “buy” rating reaffirmed by TD Cowen.
• 2/6/2026 – Adaptive Biotechnologies had its price target raised by BTIG Research from $21.00 to $22.00. They now have a “buy” rating on the stock.
• 2/6/2026 – Adaptive Biotechnologies was given a new $21.00 price target by Piper Sandler.
• 2/6/2026 – Adaptive Biotechnologies had its price target raised by JPMorgan Chase & Co. from $20.00 to $21.00. They now have an “overweight” rating on the stock.
• 1/31/2026 – Adaptive Biotechnologies was downgraded by Wall Street Zen from “buy” to “hold”.
• 1/26/2026 – Adaptive Biotechnologies had its price target raised by Guggenheim from $20.00 to $21.00. They now have a “buy” rating on the stock.
• 1/21/2026 – Adaptive Biotechnologies had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/7/2026 – Adaptive Biotechnologies had its “buy” rating reaffirmed by TD Cowen.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, insider Harlan S. Robins sold 8,120 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $19.00, for a total value of $154,280.00. Following the completion of the sale, the insider directly owned 1,179,524 shares in the company, valued at approximately $22,410,956. This represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Kyle Piskel sold 2,145 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $18.46, for a total value of $39,596.70. Following the transaction, the chief financial officer owned 216,637 shares in the company, valued at approximately $3,999,119.02. This trade represents a 0.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 870,820 shares of company stock worth $15,440,379 in the last 90 days. 6.40% of the stock is currently owned by company insiders.

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.